Ovine Cytokine/Chemokine Panel 1 14 Plex ยี่ห้อ Sigma

DESCRIPTION

General description

Immune checkpoint proteins are key regulators of the immune system and drug targets of cancer immunotherapy. Immune checkpoint molecules have been found on the cell surface of immune cells and tumor cells as activating receptors or inhibitory receptors. Immune checkpoint inhibitors, such as blocking antibodies to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1), have demonstrated significant efficacy in the treatment of a variety of cancers. Recent studies have also shown many immune checkpoint proteins can undergo alternative splicing or proteolytic cleavage to produce soluble checkpoint proteins. The expression levels of soluble and cell-surface immune checkpoint proteins in the circulation and in tumor-microenvironment (TME) may be used as putative immune-based biomarkers for cancer research and biomarker discovery in immunological diseases.

MILLIPLEX^® Mouse Immuno-Oncology Checkpoint Protein Panel 1 is a 28-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma, cell culture supernatant, cell lysate, and tissue/tumor extract samples: 4-1BBL/TNFSF9, 5′-NT/CD73, B7-H2/ICOSL, B7-H3/CD276, BCA-1/CXCL-13, BTLA, CD137/4-1BB, CD226/DNAM-1, CD25/IL-2Rα, CD27, CD40, CD80/B7-1, CTLA-4/CD152, E-cadherin, Galectin-1, Galectin-3, GITR, Granzyme B, HVEM, IFNγ, IL-10, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, TLR-2, and TNFα.

Panel Type: MAGNETIC Circulating Cancer

Specificity

Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

The Mouse Immuno-Oncology Checkpoint Protein Panel 1 bead-based multiplex panel, using the Luminex^® xMAP^® technology, enables the simultaneous analysis of 28 immune checkpoint proteins in mouse serum, plasma, cell culture supernatant, cell lysate, and tissue/tumor extract samples.

This is an overnight incubation assay (16-18 hours at 2-8ºC).

A maximum of 25 μL per well 1:2 diluted serum or plasma can be used.

Tissue culture samples may be run neat or appropriately diluted in control medium.

Note: Best results using cell/tissue lysate samples may require diluting in assay buffer while testing similarly diluted lysis buffer for matrix effects.

Research Category: Cancer/Immuno-oncology

Analytes:

4-1BBL/TNFSF9

5’-NT/CD73

B7-H2/ICOSL

B7-H3/CD276

BCA-1/CXCL-13

BTLA

CD137/4-1BB

CD226/DNAM-1

CD25/IL-2Rα

CD27

CD40

CD80/B7-1

CTLA-4/CD152

E-cadherin

Galectin-1

Galectin-3

GITR

Granzyme B

HVEM

IFNγ

IL-10

LAG-3

PD-1

PD-L1

PD-L2

TIM-3

TLR-2

TNFα

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Packaging

96-well plate

Other Notes

Sensitivity: Refer to kit protocol for sensitivities for individual cytokines/chemokines.

Legal Information

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.